Skip to content
OpenCapital
Get started

NuSkin Enterprises NUS Interest Expense, Nonoperating

Interest Expense, Nonoperating at other companies

CTO
Citius Oncology, Inc.CTOR
$33.03K—
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$258K+1,190%
XTI Aerospace, Inc. logo
XTI Aerospace, Inc.XTIA
$154K-29.0%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$153K+11.5%
Dakota Gold logo
Dakota GoldDC
$34.37K—
Evommune logo
Evommune EVMN
$25.8K-72.9%

Other financials

Income statement

See full
Revenue$320.6M-12.0%
Gross profit$214.5M-13.2%
Operating income$4.0M+141%
Net income$1.8M-98.3%
EPS (diluted)$0.04-98.1%

Balance sheet

See full
Cash & equivalents$198.7M-2.5%
Total debt$303.6M-8.2%
Total equity$794.1M+5.3%
Total assets$1.4B-1.1%

Cash flow

See full
Operating cash flow-$3.9M-1,107%
CapEx$13.7M+1.0%
Free cash flow-$17.6M-33.6%

Valuation

See full
Market cap$256.35M-38.2%

Where this comes from

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's interest expense, nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NuSkin Enterprises's interest expense, nonoperating?
NuSkin Enterprises (NUS) reported interest expense, nonoperating of $4.25M in Q1 2026.